Tag

Tirzepatide

All articles tagged with #tirzepatide

business3 days ago•2 min saved

Novo Nordisk stock slides after CagriSema misses non-inferiority vs Lilly’s tirzepatide

Novo Nordisk’s stock fell about 15% after its weight‑loss candidate CagriSema failed to demonstrate non‑inferiority to Eli Lilly’s tirzepatide over 84 weeks (23% weight loss on CagriSema vs 25.5% for tirzepatide at 84 weeks). Lilly’s drug remains dominant in the market, and Novo is pursuing higher‑dose trials while facing competition, U.S. price pressure, and looming loss of exclusivity for Wegovy and Ozempic. The stock traded at its lowest since June 2021, and Lilly stock rose in premarket trading as Novo cautioned about slower growth in 2026.

via CNBC|

#business #cagrisema #novonordisk

science3 days ago•6 min saved

Tirzepatide reduces alcohol reward in rodent study, hinting at AUD therapy

Rodents treated with tirzepatide (Mounjaro) drank more than half as much alcohol as controls, showed fewer relapse-like drinking episodes, and exhibited reduced alcohol-induced dopamine spikes in the brain’s reward center, the lateral septum. The drug also altered histone-related proteins, suggesting possible long-term neural changes. While promising, human trials are needed to confirm efficacy for alcohol use disorder, though tirzepatide’s established safety profile could speed future research.

via Neuroscience News|

#alcohol-use-disorder #dopamine #glp-1gip-dual-agonist

business22 days ago•2 min saved

Novo Nordisk Slips on 2026 Sales Outlook Amid Ozempic/Wegovy Pressure

Novo Nordisk beat 2025 sales estimates but warned that 2026 sales will fall 5%–13% at constant exchange rates, reversing last year’s growth. The drop is driven by expected weaker U.S. sales amid competition from Lilly’s tirzepatide and pricing pressures under MFN reforms, even as international sales may rise with Wegovy expanding into more markets. The outlook sent the stock lower, with U.S.-listed shares sliding about 14% after the report.

via Barron's|

#2026-sales-decline #business #novo-nordisk

health23 days ago•57 min saved

UK reports triple-digit rise in Mounjaro side effects in 2025, with 71 deaths

UK health chiefs recorded 40,245 adverse reactions to the diabetes/weight-loss jab Mounjaro in 2025 (6,755 serious; 71 deaths), a roughly 340% rise from 2024. Gastrointestinal disorders were the most common reaction (37,546 reports, 19 fatal). The NHS notes symptoms like nausea and diarrhea, while patients report severe side effects. Eli Lilly says safety is a priority and that risks are monitored. The MHRA updated product info to include a small risk of severe acute pancreatitis for Mounjaro (as well as Wegovy and Ozempic). Regulators stress benefits often outweigh risks, and urge patients to consult doctors about side effects. In the UK, around 1.6 million people are said to have used these lipids-lowering injections in the past year.

via Daily Mail|

#adverse-effects #health #mhra

health27 days ago•5 min saved

GLP-1 Drugs in 2026: A Practical Guide to Today’s Options and the Pipeline

An up-to-date primer on GLP-1 therapies through 2026, detailing approved drugs (Ozempic, Wegovy, Rybelsus, Mounjaro/Zepbound, Victoza/Saxenda, Trulicity, Byetta/Bydureon, Adlyxin/Lyxumia) and promising ones (orforglipron, retatrutide), their dosing (daily vs weekly), diabetes vs obesity uses, and safety notes (thyroid tumor risk), plus the state of generics and the 2026 pipeline.

via New York Post|

#diabetes #glp-1 #health

business3 months ago•2 min saved

Eli Lilly's Mounjaro and Zepbound Drive Record Sales and Growth

Eli Lilly's weight loss and diabetes drug tirzepatide has surpassed Merck's Keytruda as the world's best-selling medicine, driven by rapid sales growth since its approval in 2022, highlighting intense competition in the pharmaceutical market for obesity and diabetes treatments.

via statnews.com|

#business #eli-lilly #keytruda

health5 months ago•3 min saved

Weight Loss Drugs Significantly Reduce Heart Attack and Stroke Risks

A large study shows that weight loss drugs like semaglutide and tirzepatide can significantly reduce the risk of hospitalization and early death in heart failure patients with obesity and type 2 diabetes, potentially offering a new treatment avenue for these patients.

via The Guardian|

#glp-1-agonists #health #heart-failure

health6 months ago•11 min saved

GLP-1 Treatment Eases Rheumatoid Arthritis and Weight Issues

Cassandra Smith, a 30-year-old with rheumatoid arthritis and obesity, experienced significant health improvements—including no flare-ups and substantial weight loss—after starting compounded tirzepatide, a GLP-1 medication, which also helped her improve her quality of life and mental health.

via yahoo.com|

#autoimmune #glp-1 #health

business7 months ago•0 min saved

Eli Lilly Advances in Obesity and Diabetes Treatments

Eli Lilly's Tirzepatide has outperformed competitors like Novo's Semaglutide in glucose control and weight loss, strengthening Lilly's market position with promising future drugs and undervalued stock potential, as the competitive landscape in the GLP-1 space shifts.

via Seeking Alpha|

#business #competition #eli-lilly

health7 months ago•2 min saved

Hormone Therapy Enhances Tirzepatide's Weight Loss Effects in Postmenopausal Women

A study presented at ENDO 2025 found that combining menopause hormone therapy with tirzepatide significantly enhances weight loss in postmenopausal women with overweight or obesity, with those using both treatments experiencing greater weight loss and higher rates of achieving at least 20% total body weight loss compared to tirzepatide alone.

via ScienceDaily|

#health #hormone-therapy #menopause

healthcare8 months ago•14 min saved

Lilly Launches Full Range of Zepbound Doses via LillyDirect

Eli Lilly announced that all approved doses of Zepbound (tirzepatide) for obesity treatment will be available in single-dose vials for $499/month or less through LillyDirect's Self Pay Pharmacy Solutions, making the medication more accessible regardless of insurance, with shipments starting in early August.

via Eli Lilly and Company|

#healthcare #lillydirect #obesity

health8 months ago•6 min saved

Real-World Effectiveness of Obesity Injections May Be Lower Than Clinical Trials

Real-world use of semaglutide and tirzepatide results in less weight loss than clinical trials, mainly due to early discontinuation and lower doses, but still shows benefits in glycemic control and diabetes prevention, highlighting the importance of persistence and optimal dosing.

via Medscape|

#glp-1-medications #health #real-world-study

health1 year ago•4 min saved

UK Limits Access to High-Demand Weight Loss Drug Mounjaro

Mounjaro, a weight loss drug containing tirzepatide, is set to be available on the NHS but will be prioritized for those with the highest needs due to high demand and potential strain on NHS resources. Unlike Wegovy, Mounjaro mimics two hormones, GLP-1 and GIP, leading to greater weight loss. Approved for adults with a BMI of 30 or more, or 27 with weight-related health issues, its rollout will span 12 years to manage demand and protect other NHS services. While effective, experts stress the need for comprehensive obesity management beyond medication.

via The Guardian|

#health #mounjaro #nhs

health1 year ago•4 min saved

Weight Loss Drugs Show Unexpected Heart Health Benefits

Recent studies published in the Journal of the American College of Cardiology reveal that anti-obesity drugs like tirzepatide and semaglutide offer significant cardiovascular benefits beyond weight loss. These medications improve cardiac structure and function in heart failure patients and enhance outcomes for those who have undergone cardiac bypass surgery. Additionally, lifestyle interventions for weight loss in Type 2 diabetes patients can alter cardiac biomarkers, potentially reducing the risk of cardiovascular disease and heart failure.

via SciTechDaily|

#cardiovascularhealth #health #heartfailure

health1 year ago•2 min saved

Eli Lilly's Tirzepatide Shows Promise for Obesity-Related Heart Failure and Diabetes Prevention

Eli Lilly's drug tirzepatide, marketed as Zepbound/Mounjaro, has shown significant cardiovascular benefits in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), according to results from the SUMMIT Phase 3 trial. The study demonstrated a 38% reduction in the risk of cardiovascular mortality and worsening heart failure events, along with improvements in heart failure symptoms and physical limitations. The trial also reported a 56% reduction in heart failure hospitalizations and significant weight loss among participants. Eli Lilly is seeking to extend tirzepatide's labeling for HFpEF and obesity with regulatory submissions.

via Yahoo Finance|

#clinical-trial #eli-lilly #health